NRG Oncology RTOG 0415: A randomized phase III non-inferiority study comparing two fractionation schedules in patients with low-risk prostate cancer

被引：25

作者：

Lee, W. Robert

Dignam, James J.

Amin, Mahul

Bruner, Deborah

Low, Daniel

Swanson, Gregory P.

Shah, Amit

D'Souza, David

Michalski, Jeff M.

Dayes, Ian

Seaward, Samantha A.

Hall, William Adrian

Nguyen, Paul L.

Pisansky, Thomas Michael

Faria, Sergio

Chen, Yuhchyau

Koontz, Bridget F.

Paulus, Rebecca

Sandler, Howard M.

机构：

[1] Duke Univ, Sch Med, Durham, NC USA

[2] Univ Chicago, Chicago, IL 60637 USA

[3] Cedars Sinai Med Ctr, Los Angeles, CA 90048 USA

[4] Emory Univ, Winship Canc Inst, Atlanta, GA 30322 USA

[5] Univ Calif Los Angeles, Los Angeles, CA USA

[6] Univ Texas Hlth Sci Ctr San Antonio, San Antonio, TX 78229 USA

[7] York Canc Ctr, York, PA USA

[8] London Reg Canc Program, Dept Radiat Oncol, London, ON, Canada

[9] Washington Univ, Sch Med, St Louis, MO USA

[10] McMaster Univ, Hamilton, ON, Canada

[11] Kaiser Permanente, Santa Clara, CA USA

[12] Med Coll Wisconsin, Milwaukee, WI 53226 USA

[13] Brigham & Womens Hosp, Dana Farber Canc Inst, 75 Francis St, Boston, MA 02115 USA

[14] Mayo Clin, Rochester, MN USA

[15] McGill Univ, Montreal, PQ, Canada

[16] Univ Rochester, Med Ctr, Rochester, NY 14642 USA

[17] Duke Univ, Med Ctr, Durham, NC USA

[18] NRG Oncol, Philadelphia, PA USA

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2016年 / 34卷 / 02期

关键词：

D O I：

10.1200/jco.2016.34.2_suppl.1

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页数：1

共 50 条

[21] Patient-Reported Outcomes in NRG Oncology/RTOG 0938, a Randomized Phase 2 Study Evaluating 2 Ultrahypofractionated Regimens (UHRs) for Prostate Cancer
Lukka, H.
Stephanie, P.
Bruner, D.
Bahary, J. P.
Lawton, C. A. F.
Efstathiou, J. A.
Kudchadker, R.
Ponsky, L.
Seaward, S. A.
Dayes, I. S.
Gopaul, D. D.
Michalski, J. M.
Delouya, G.
Kaplan, I. D.
Horwitz, E. M.
Roach, M., III
Pinover, W. H.
Beyer, D. C.
Sandler, H. M.
Kachnic, L. A.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2016, 94 (01): : 2 - 2
[22] Biopsy-based basal-luminal subtyping classifier in high-risk prostate cancer: Analysis of the NRG Oncology/RTOG 9202, 9413, and 9902 randomized phase III trials
Nguyen, P.
Liu, V.
Proudfoot, J. A.
Davicioni, E.
Liu, Y.
Dal Pra, A.
Spratt, D. E.
Sandler, H. M.
Efstathiou, J. A.
Lawton, C.
Simko, J. P.
Rosenthal, S.
Zeitzer, K.
Mendez, L.
Hartford, A.
Hall, W.
Desai, A.
Pugh, S.
Tran, P. T.
Feng, F.
ANNALS OF ONCOLOGY, 2022, 33 (07) : S1172 - S1173
[23] Early switch to oral antibiotic therapy in patients with low-risk neutropenic sepsis (EASI-SWITCH): a randomized non-inferiority trial
Coyle, Vicky
Forde, Caroline
Mcauley, Danny F.
Wilson, Richard H.
Clarke, Mike
Plummer, Ruth
Grayson, Margaret
Mcdowell, Cliona
Agus, Ashley
Doran, Annmarie
Thomas, Anne L.
Barnes, Rosemary A.
Adams, Richard
Chau, Ian
Storey, Dawn
McMullan, Ronan
CLINICAL MICROBIOLOGY AND INFECTION, 2024, 30 (01) : 92 - 99
[24] A non-inferiority randomized phase III trial of standard immunotherapy versus reduced dose intensity in responding patients with metastatic cancer: MOIO study
Gravis, Gwenaelle
Olive, Daniel
Marino, Patricia
Penault-Llorca, Frederique Madeleine
Delord, Jean-Pierre
Lamrani-Ghaouti, Assia
Simon, Clotilde
Sabatier, Renaud
Ciccolini, Joseph
Boher, Jean-Marie
JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
[25] Radiotherapy alone vs radiotherapy with concurrent chemoradiotherapy in patients with low-risk nasopharyngeal carcinoma: Updated results from a multicenter, open-label, non-inferiority, randomized phase III trial.
Guo, Rui
Zhang, Yuan
Zhang, Ning
Deng, Bin
Cheng, Zhi-Bin
Huang, Jing
Zhang, Fan
Mao, Yan-Ping
Li, Wen-Fei
Zhou, Guan-Qun
Chen, Yu-Pei
Xu, Cheng
Lin, Li
Zhang, Wei-Wei
Jiang, Xu
Liu, Qing
Sun, Ying
Ma, Jun
Chen, Lei
JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (23_SUPPL) : 142 - 142
[26] AN OPEN, RANDOMIZED, MULTICENTRE, PHASE III TRIAL COMPARING THE EFFICACY OF TWO TAMOXIFEN SCHEDULES IN PREVENTING GYNAECOMASTIA INDUCED BY BICALUTAMIDE MONOTHERAPY IN PROSTATE CANCER PATIENTS
Bedognetti, Davide
Rubagotti, Alessandra
Conti, Giario
Francesca, Francesco
De Cobelli, Ottavio
Canclini, Luca
Gallucci, Michele
Aragona, Francesco
Di Tonno, Pasquale
Cortellini, Pietro
Martorana, Giuseppe
Lapini, Alberto
Boccardo, Francesco
ANNALS OF ONCOLOGY, 2009, 20
[27] (ICORG 05-03): prospective randomized non-inferiority phase III trial comparing two radiation schedules in malignant spinal cord compression (not proceeding with surgical decompression); the quality of life analysis
Lee, K. A.
Dunne, M.
Small, C.
Kelly, P. J.
McArdle, O.
O'Sullivan, J.
Hacking, D.
Pomeroy, M.
Armstrong, J.
Moriarty, M.
Clayton-Lea, A.
Parker, I
Collins, C. D.
Thirion, P.
ACTA ONCOLOGICA, 2018, 57 (07) : 965 - 972
[28] Long Term Follow-up on NRG Oncology RTOG 0915 (NCCTG N0927): a Randomized Phase II Study of 2 SBRT Schedules for Lung Cancer
Videtic, G.
Paulus, R.
Singh, A.
Chang, J.
Parker, W.
Olivier, K.
Timmerman, R.
Komaki, R.
Urbanic, J.
Stephans, K.
Yom, S.
Robinson, C.
Belani, C.
Iyengar, P.
Ajlouni, M.
Gopaul, D.
Lele, S.
Mcgarry, R.
Choy, H.
Bradley, J.
JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (11) : S1853 - S1854
[29] Effect of Chemotherapy With Docetaxel With Androgen Suppression and Radiotherapy for Localized High-Risk Prostate Cancer: The Randomized Phase III NRG Oncology RTOG 0521 Trial (vol 37, pg 1159, 2019)
Rosenthal, Seth A.
JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (17) : 1949 - 1949
[30] Randomized phase III trial to evaluate radiopharmaceuticals and zoledronic acid in the palliation of osteoblastic metastases from lung, breast, and prostate cancer: report of the NRG Oncology RTOG 0517 trial
Michael J. Seider
Stephanie L. Pugh
Corey Langer
Gwen Wyatt
William Demas
Afshin Rashtian
Cathy L. Clausen
Jerome David Derdel
Sean F. Cleary
Christopher A. Peters
Ashok Ramalingam
James E. Clarkson
Michael Tomblyn
Rachel A. Rabinovitch
Lisa A. Kachnic
Lawrence B. Berk
Annals of Nuclear Medicine, 2018, 32 : 553 - 560

← 1 2 3 4 5 →